InternaView membership options
[Comment] Prasinezumab: what have we learned from PASADENA and PADOVA?
VIP articleThe concept of slowing down Parkinson's disease progression by using an antibody targeting aggregating forms of α-synuclein is intuitively very appealing. However, demonstrating efficacy of a potential disease-modifying therapy is highly challenging and a consensus has not been reached on the optimal trial design.1 The
ME
MedScopeGlobal Editorial
May 29, 2026
InternaVIP
Evidence-based clinical briefing
[Comment] Prasinezumab: what have
MedScope VIP
This article is reserved for VIP subscribers. Upgrade for full access, an ad-free reading experience, and priority clinical alerts.
Doporučený obsah
Články
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Synergistic Renoprotective Effects of Moderate-Intensity Resistance Training and Vitamin D Supplementation on a Type 2 Diabetic Nephropathy Rat Model
- Diagnostika a screening u nejčastějších symptomů
Studie
- RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings
- Upskilling Rheumatology Occupational Therapists in Work Rehabilitation: An Evaluation of a Job Retention Vocational Rehabilitation Training Course (the Workwell Trial)
- Satisfaction with telemedicine versus in-person visits in rheumatology: a noninferiority randomised controlled trial